Placebo of HM15211

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

NAFLDNASH - Nonalcoholic Steatohepatitis

Phase 1

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

CompletedNCT03744182

Hanmi Pharmaceutical Company LimitedNAFLD

Start: 2018-11-01End: 2020-03-18Updated: 2025-01-27

Phase 2

Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

CompletedNCT04505436

Hanmi Pharmaceutical Company LimitedNASH - Nonalcoholic Steatohepatitis

Start: 2020-07-31End: 2026-07-15Updated: 2026-08-19

Related Papers

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations